Cantor Fitzgerald Reiterates Overweight on Vaxcyte, Announces $120 Price Target

Benzinga · 2d ago
Cantor Fitzgerald analyst Carter Gould reiterates Vaxcyte (NASDAQ:PCVX) with a Overweight and announces $120 price target.